A detailed history of Pnc Financial Services Group, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 10,061 shares of HALO stock, worth $492,989. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,061
Previous 11,616 13.39%
Holding current value
$492,989
Previous $608,000 5.43%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$51.3 - $64.42 $79,771 - $100,173
-1,555 Reduced 13.39%
10,061 $575,000
Q2 2024

Aug 09, 2024

BUY
$37.81 - $52.4 $4,953 - $6,864
131 Added 1.14%
11,616 $608,000
Q1 2024

May 10, 2024

BUY
$33.68 - $41.95 $4,075 - $5,075
121 Added 1.06%
11,485 $467,000
Q4 2023

Feb 09, 2024

SELL
$33.32 - $42.1 $16,626 - $21,007
-499 Reduced 4.21%
11,364 $420,000
Q3 2023

Nov 13, 2023

SELL
$36.46 - $44.03 $28,584 - $34,519
-784 Reduced 6.2%
11,863 $453,000
Q2 2023

Aug 11, 2023

BUY
$30.28 - $38.74 $1,029 - $1,317
34 Added 0.27%
12,647 $456,000
Q1 2023

May 15, 2023

SELL
$32.86 - $55.7 $68,283 - $115,744
-2,078 Reduced 14.14%
12,613 $481,000
Q4 2022

Feb 10, 2023

SELL
$40.06 - $59.44 $124,706 - $185,036
-3,113 Reduced 17.48%
14,691 $835,000
Q3 2022

Nov 10, 2022

BUY
$38.53 - $51.78 $25,930 - $34,847
673 Added 3.93%
17,804 $703,000
Q2 2022

Aug 12, 2022

BUY
$37.35 - $48.3 $11,391 - $14,731
305 Added 1.81%
17,131 $753,000
Q1 2022

May 12, 2022

BUY
$31.97 - $41.06 $129,990 - $166,949
4,066 Added 31.87%
16,826 $671,000
Q4 2021

Feb 11, 2022

SELL
$31.82 - $40.75 $293,666 - $376,081
-9,229 Reduced 41.97%
12,760 $513,000
Q3 2021

Nov 05, 2021

BUY
$38.47 - $46.42 $177,308 - $213,949
4,609 Added 26.52%
21,989 $894,000
Q2 2021

Aug 06, 2021

SELL
$38.84 - $51.31 $35,927 - $47,461
-925 Reduced 5.05%
17,380 $789,000
Q1 2021

May 07, 2021

BUY
$39.51 - $51.45 $106,439 - $138,606
2,694 Added 17.26%
18,305 $763,000
Q4 2020

Feb 12, 2021

SELL
$25.81 - $43.62 $597,682 - $1.01 Million
-23,157 Reduced 59.73%
15,611 $666,000
Q3 2020

Nov 06, 2020

BUY
$25.74 - $29.63 $2,805 - $3,229
109 Added 0.28%
38,768 $1.02 Million
Q2 2020

Aug 07, 2020

SELL
$16.25 - $26.81 $97,955 - $161,610
-6,028 Reduced 13.49%
38,659 $1.04 Million
Q1 2020

May 08, 2020

BUY
$13.9 - $21.83 $83,747 - $131,525
6,025 Added 15.58%
44,687 $803,000
Q4 2019

Feb 07, 2020

SELL
$14.93 - $19.53 $4,897 - $6,405
-328 Reduced 0.84%
38,662 $685,000
Q3 2019

Nov 08, 2019

BUY
$15.2 - $17.69 $1,322 - $1,539
87 Added 0.22%
38,990 $604,000
Q2 2019

Aug 09, 2019

BUY
$14.75 - $17.26 $2,950 - $3,452
200 Added 0.52%
38,903 $0
Q1 2019

May 10, 2019

BUY
$13.94 - $17.58 $125 - $158
9 Added 0.02%
38,703 $0
Q2 2018

Aug 10, 2018

SELL
$16.87 - $20.3 $101 - $121
-6 Reduced 0.02%
38,694 $0
Q1 2018

May 11, 2018

SELL
$17.06 - $21.2 $16,957 - $21,072
-994 Reduced 2.5%
38,700 $0
Q4 2017

Feb 09, 2018

BUY
$16.75 - $20.8 $648,124 - $804,835
38,694 Added 3869.4%
39,694 $0
Q3 2017

Nov 13, 2017

BUY
$11.76 - $17.4 $11,760 - $17,400
1,000
1,000 $0

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.83B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.